Novo holds off generic competition

Posted 19 December 2024 AM

Novo Nordisk's diabetes drug Victoza will remain under patent protection until August next year after a judge rejected the idea that a formulation cannot be patented as a pharmaceutical substance.

Generics company Cipla filed suit in April this year, arguing that a patent term extension should not have been granted for patent 2004290862, Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices, and asking the Register of Patents record be changed so that it expires on 18 November 2024.

To see the whole article, please login